Last reviewed · How we verify
interleukin 23
At a glance
| Generic name | interleukin 23 |
|---|---|
| Sponsor | Sohag University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (PHASE3)
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
- A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant (PHASE2)
- Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- interleukin 23 CI brief — competitive landscape report
- interleukin 23 updates RSS · CI watch RSS
- Sohag University portfolio CI